Physician profile
Michael Park
NPI 1831611177
$3,658.65
in general payments reported to CMS, 2019-2025
13 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $450 · 2023: $1,994 · 2024: $644 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Honoraria: $1,390 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.47 |
| Honoraria | $1,390.00 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,133.96 | 2022-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $492.63 | 2023-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $213.08 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $185.56 | 2024-2025 | Syfovre |
| Neurotech Pharmaceuticals, INC. | $158.28 | 2025 | |
| Alcon Vision LLC | $148.89 | 2023 | Clareon |
| Eyepoint US, INC. | $124.99 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $100.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $36.96 | 2025 | Yutiq, Iluvien |
| Merck Sharp & Dohme LLC | $18.96 | 2023 | Verquvo |
| Sandoz INC. | $17.03 | 2024 | Cimerli |
| Astellas Pharma US INC | $14.93 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $13.38 | 2023 | Visudyne, Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.